Processing

Please wait...

Settings

Settings

Goto Application

1. WO2020117759 - SMALL MOLECULE DEGRADERS OF HELIOS AND METHODS OF USE

Publication Number WO/2020/117759
Publication Date 11.06.2020
International Application No. PCT/US2019/064169
International Filing Date 03.12.2019
IPC
A61K 31/454 2006.01
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
31Medicinal preparations containing organic active ingredients
33Heterocyclic compounds
395having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
435having six-membered rings with one nitrogen as the only ring hetero atom
44Non-condensed pyridines; Hydrogenated derivatives thereof
445Non-condensed piperidines, e.g. piperocaine
4523containing further heterocyclic ring systems
454containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
A61K 31/4545 2006.01
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
31Medicinal preparations containing organic active ingredients
33Heterocyclic compounds
395having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
435having six-membered rings with one nitrogen as the only ring hetero atom
44Non-condensed pyridines; Hydrogenated derivatives thereof
445Non-condensed piperidines, e.g. piperocaine
4523containing further heterocyclic ring systems
4545containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
A61K 31/4725 2006.01
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
31Medicinal preparations containing organic active ingredients
33Heterocyclic compounds
395having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
435having six-membered rings with one nitrogen as the only ring hetero atom
47Quinolines; Isoquinolines
472Non-condensed isoquinolines, e.g. papaverine
4725containing further heterocyclic rings
A61K 31/496 2006.01
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
31Medicinal preparations containing organic active ingredients
33Heterocyclic compounds
395having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
495having six-membered rings with two nitrogen atoms as the only ring hetero atoms, e.g. piperazine
496Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene
Applicants
  • DANA-FARBER CANCER INSTITUTE, INC. [US]/[US]
Inventors
  • VERANO, Alyssa
  • WANG, Eric
  • NOWAK, Radoslaw
  • YUAN, Christine
  • GRAY, Nathanael
  • FISCHER, Eric
  • ZHANG, Tinghu
  • LIU, Hu
Agents
  • CLARKE, J.D.,PH.D., Daniel W.
  • JOBSE, Bruce, D.
  • SERIO, John, C.
  • COHEN, Jerry
  • GOLDMAN, Gabriel
  • GOMES, David, W.
  • HAASAN, Shahid
  • LOPEZ, Orlando
  • MARAIA, Joseph
  • MILLS, Stephen
  • MOORE, Ronda
  • QUINN, Joseph, P.
  • SCHEPPER, Marlo
  • SORKIN, Paul
  • SUSAN, Janine
  • MCGRATH, Daniel
  • CHACLAS, George
  • COWLES, Christopher
  • EMMONS, Richard
  • FOLEY, Shawn
  • KARIMI, Pegah
  • DUBEROW, Eilene
Priority Data
62/774,48203.12.2018US
62/938,41021.11.2019US
Publication Language English (EN)
Filing Language English (EN)
Designated States
Title
(EN) SMALL MOLECULE DEGRADERS OF HELIOS AND METHODS OF USE
(FR) AGENTS DE DÉGRADATIONS DE PETITES MOLÉCULES DE HELIOS ET PROCÉDÉS D'UTILISATION
Abstract
(EN)
Disclosed are compounds and pharmaceutically acceptable salts and stereoisomers thereof that may cause degradation of various proteins e.g., IKZF2 (Helios). Also disclosed are pharmaceutical compositions containing same, and methods of making and using the compounds to treat diseases and disorders characterized or mediated by aberrant protein activity.
(FR)
L'invention concerne des composés et des sels pharmaceutiquement acceptables et des stéréo-isomères de ceux-ci qui peuvent provoquer la dégradation de diverses protéines, par exemple IKZF2 (Helios). L'invention concerne également des compositions pharmaceutiques les contenant et des méthodes de fabrication et d'utilisation des composés pour traiter des maladies et des troubles caractérisés ou médiés par une activité protéique aberrante.
Latest bibliographic data on file with the International Bureau